Elevance Health Inc. (ELV) AI Stock Analysis

Elevance Health Inc., formerly known as Anthem, Inc., is a health benefits company headquartered in Indianapolis, Indiana. Established in 1944, the company rebranded in June 2022 to emphasize holistic health management and community engagement. Elevance Health delivers a comprehensive range of medical, digital, pharmacy, behavioral, clinical, and care solutions, serving approximately 118 million people globally. Operating through strategic partnerships and customer-centric approaches, it provides personalized care plans and integrated health management solutions to enhance well-being and elevate healthcare delivery standards.

Elevance Health increased revenue from $138.64B in FY2021 to $199.12B in FY2025, recording a 5-year revenue CAGR of 10.3%. Annual revenue grew 12.6% in FY2025, up from 3.2% growth in FY2024. However, net margin declined from 4.4% in FY2021 to 2.8% in FY2025, with net income falling to $5.66B and EPS dropping to $30.17 from $32.97 in FY2024. In the latest quarter ended June 30, 2026, quarterly revenue grew 1.4% year-over-year, while quarterly earnings declined 13.1%. Over the trailing twelve months, revenue totaled $201.11B with an operating margin of 4.6% and net profit margin of 2.5%.

As of June 30, 2026, Elevance Health held $37.51B in cash and short-term investments against total debt of $31.04B, resulting in net cash of $6.47B. The company reported a current ratio of 2.05, shareholders' equity of $44.88B, and a debt-to-equity ratio of 0.69. In FY2025, operating cash flow was $4.29B and free cash flow stood at $3.17B. Elevance Health directed capital toward $1.12B in capital expenditures, $2.60B in share buybacks, and $1.53B in dividends paid, reducing its 5-year share count by 11.2%.

At a last close of $428.26, Elevance Health trades at a trailing P/E of 19.0x and a forward P/E of 13.7x, both below the median of its S&P 500 Healthcare peers of 28.9x and 16.6x, respectively. Its price-to-sales ratio is 0.5x compared to the peer median of 3.4x, and its PEG ratio is 1.30. Over the past year, ELV gained 25.4%, outpacing the S&P 500 return of 16.8%. Over a 5-year period, its 17.2% return trailed the S&P 500 return of 83.0%.

Elevance Health pays a quarterly dividend with an annual forward dividend of $6.88 per share, representing a 1.61% dividend yield. The company maintains a payout ratio of 23.4% and has paid dividends for 16 consecutive years. Over the last five years, dividend growth annualized reached 12.5%, with the most recent ex-dividend date on September 10, 2026.

Wall Street coverage comprises 12 Strong Buy, 2 Buy, and 8 Hold ratings, with zero Sell or Strong Sell recommendations. The mean price target is $451.71, indicating a 5.5% premium to the last close of $428.26. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $196.44B and EPS of $27.24, implying an EPS decline of 10.1%. Elevance Health beat EPS estimates in each of the last 4 quarters, with next earnings scheduled for October 21, 2026.

This page is an AI-written research summary of Elevance Health Inc. (ELV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ELV income statement, ELV balance sheet, ELV key metrics, ELV analyst forecast, ELV chart. See the ELV stock overview for the latest quote and news.